Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

118 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.
Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC, Candoni A, Récher C, Sandhu I, Bernal del Castillo T, Al-Ali HK, Martinelli G, Falantes J, Noppeney R, Stone RM, Minden MD, McIntyre H, Songer S, Lucy LM, Beach CL, Döhner H. Dombret H, et al. Among authors: wierzbowska a. Blood. 2015 Jul 16;126(3):291-9. doi: 10.1182/blood-2015-01-621664. Epub 2015 May 18. Blood. 2015. PMID: 25987659 Free PMC article. Clinical Trial.
The treatment of acute myeloid leukemia with mitoxantrone, etoposide and low-dose cytarabine in elderly patients - a report of Polish Acute Leukemia Group (PALG) phase II study.
Wrzesien-Kus A, Robak T, Jamroziak K, Wierzbowska A, Dmoszynska A, Adamczyk-Cioch M, Kuliczkowski K, Mazur G, Holowiecki J, Konopka L, Maj S, Marianska B, Zawilska K; Polish Acute Leukemia Group (PALG) phase II study. Wrzesien-Kus A, et al. Among authors: wierzbowska a. Neoplasma. 2002;49(6):405-11. Neoplasma. 2002. PMID: 12584589 Clinical Trial.
Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group.
Wierzbowska A, Robak T, Pluta A, Wawrzyniak E, Cebula B, Hołowiecki J, Kyrcz-Krzemień S, Grosicki S, Giebel S, Skotnicki AB, Piatkowska-Jakubas B, Kuliczkowski K, Kiełbiński M, Zawilska K, Kłoczko J, Wrzesień-Kuś A; Polish Adult Leukemia Group. Wierzbowska A, et al. Eur J Haematol. 2008 Feb;80(2):115-26. doi: 10.1111/j.1600-0609.2007.00988.x. Epub 2007 Dec 11. Eur J Haematol. 2008. PMID: 18076637
Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.
Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, Gau JP, Chou WC, Buckstein R, Cermak J, Kuo CY, Oriol A, Ravandi F, Faderl S, Delaunay J, Lysák D, Minden M, Arthur C. Kantarjian HM, et al. Among authors: wierzbowska a. J Clin Oncol. 2012 Jul 20;30(21):2670-7. doi: 10.1200/JCO.2011.38.9429. Epub 2012 Jun 11. J Clin Oncol. 2012. PMID: 22689805 Free PMC article. Clinical Trial.
Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogenetics.
Mayer J, Arthur C, Delaunay J, Mazur G, Thomas XG, Wierzbowska A, Ravandi F, Berrak E, Jones M, Li Y, Kantarjian HM. Mayer J, et al. Among authors: wierzbowska a. BMC Cancer. 2014 Feb 6;14:69. doi: 10.1186/1471-2407-14-69. BMC Cancer. 2014. PMID: 24498872 Free PMC article. Clinical Trial.
Post hoc analysis of the relationship between baseline white blood cell count and survival outcome in a randomized Phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia.
Arthur C, Cermak J, Delaunay J, Mayer J, Mazur G, Thomas X, Wierzbowska A, Jones MM, Berrak E, Kantarjian H. Arthur C, et al. Among authors: wierzbowska a. J Blood Med. 2015 Jan 8;6:25-9. doi: 10.2147/JBM.S64067. eCollection 2015. J Blood Med. 2015. PMID: 25678833 Free PMC article.
Cladribine added to daunorubicin-cytarabine induction prolongs survival of FLT3-ITD+ normal karyotype AML patients.
Libura M, Giebel S, Piatkowska-Jakubas B, Pawelczyk M, Florek I, Matiakowska K, Jazwiec B, Borg K, Solarska I, Zawada M, Czekalska S, Libura J, Jakobczyk M, Karabin K, Paluszewska M, Calbecka M, Gajkowska-Kulik J, Gadomska G, Kielbinski M, Ejduk A, Kata D, Grosicki S, Wierzbowska A, Kyrcz-Krzemien S, Warzocha K, Kuliczkowski K, Skotnicki A, Holowiecki J, Jedrzejczak WW, Haus O. Libura M, et al. Among authors: wierzbowska a. Blood. 2016 Jan 21;127(3):360-2. doi: 10.1182/blood-2015-08-662130. Epub 2015 Nov 13. Blood. 2016. PMID: 26567156 Free article. No abstract available.
118 results